DM2

OASYX Welcomes Hajime Nakatani and Bandai Namco Research to "OASYX Series 2: RYUZO" NFT Project

Retrieved on: 
Thursday, June 29, 2023
DM2, Blockchain, NFT, Bandai, Bandai Namco Entertainment, Research, DJT, Bandai Namco Studios, Starblade, Non-fungible token, Verse, Growth, AI, SBT, Environment, Behavior, Egg, Video game, Cryptocurrency, OASYS, XR

"OASYX series 2: RYUZO" is a nurturing NFT project using AI technology, with a total of 10,000 units issued. Users can acquire "MARYU" (equivalent to eggs) and hatch them into "RYU". After hatching, "RYU" becomes a non-transferable NFT called SBT -- Soulbound Token, an NFT that cannot be transferred to other users. "RYU" can be nurtured and trained using AI technology jointly developed by Bandai Namco Research and Attructure, a company researching AI and artificial life.

Key Points: 
  • The project will be supervised by Hajime Nakatani, an advisor to Oasys, known for his work on popular titles, including the "Tekken" series.
  • "OASYX series 2: RYUZO" is a nurturing NFT project using AI technology, with a total of 10,000 units issued.
  • Hajime Nakatani, who worked as a director and studio supervisor at Bandai Namco Games, will supervise the overall theme and art direction of the second series.
  • Hajime Nakatani added: "RYUZO", the second title of OASYX, is a project realized in collaboration with Bandai Namco Research, Attructure, Oasys, and DJT (double jump.tokyo).

Rep Data Study Shows Impact of Audience Characteristics on Data Quality

Retrieved on: 
Thursday, November 17, 2022
Algorithm, University, Social, Digital, Data collection, Mobile, AOL, Research, Multimedia, DM2, Risk, WarnerMedia, Public relations, Retail, Online shopping

NEW ORLEANS, Nov. 17, 2022 /PRNewswire/ -- Rep Data, a full-service data collection firm for quantitative primary research, and DM2 (Digital Marketing & Measurement), today released a new research-on-research report, "How are today's survey respondents affecting your data quality?" The report illustrates the impact of audience characteristics and behaviors on market research outcomes, furthering the ongoing exploration of factors impacting data quality in the insights space. "Issues surrounding data quality in the market research space are persistent, evolving and complex. This unfortunately has not changed over the two decades that I've spent working in this industry," said Jeremy Antoniuk, COO of Rep Data. "If researchers want to trust their data again, we must understand exactly which elements in the research process impact data quality. This insightful study shows one of the key factors is the composition of the survey audience - factors which can be improved through better sourcing, expert project management and intelligent sample aggregation."

Key Points: 
  • The report illustrates the impact of audience characteristics and behaviors on market research outcomes, furthering the ongoing exploration of factors impacting data quality in the insights space.
  • "If researchers want to trust their data again, we must understand exactly which elements in the research process impact data quality.
  • The report not only examines the impact of audience demographics and characteristics on data quality, but also provides a review of data surrounding the quality of responses based on the device used to complete surveys.
  • Rep Data provides full-service data collection solutions for primary researchers, helping expedite data collection for primary quantitative research studies, with a hyper-focus on data quality and consistent execution.

Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting

Retrieved on: 
Tuesday, March 29, 2022
LinkedIn, DM1, Therapy, Diagnosis, AOC, Pharmacokinetics, Patient, Avidity, RNA, Prevalence, Twitter, Nasdaq, MARINA, American Academy, Science, AOCS, SAN, FSHD, Myotonic dystrophy, DMD, Insan, Antibody-oligonucleotide conjugate, DM2, Adult, Vaccine, Safety

SAN DIEGO, March 29, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs),today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington, April 2-7, 2022.

Key Points: 
  • SAN DIEGO, March 29, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs),today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington, April 2-7, 2022.
  • Avidity is on track to have three programs in clinical development by the end of 2022.
  • The company's lead product candidate, AOC 1001, is designed to treat patients with myotonic dystrophy type 1 (DM1).
  • Avidity anticipates both programs will enter the clinic by the end of 2022.